219 related articles for article (PubMed ID: 10905514)
1. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis.
Zhang R; Zhang H; Wei H; Luo X
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):95-7. PubMed ID: 10905514
[TBL] [Abstract][Full Text] [Related]
2. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
3. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
Aziz SA; Pervez S; Khan SM; Kayani N; Nasir MI
J Coll Physicians Surg Pak; 2005 Apr; 15(4):225-9. PubMed ID: 15857596
[TBL] [Abstract][Full Text] [Related]
5. Metallothionein expression in invasive and in situ breast carcinomas.
Gallicchio LM; Flaws JA; Fowler BA; Ioffe OB
Cancer Detect Prev; 2005; 29(4):332-7. PubMed ID: 16122884
[TBL] [Abstract][Full Text] [Related]
6. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
7. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer.
Jin R; Bay BH; Chow VT; Tan PH; Lin VC
Br J Cancer; 2000 Aug; 83(3):319-23. PubMed ID: 10917545
[TBL] [Abstract][Full Text] [Related]
9. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype.
Wang J; Liu Y; Ji R; Gu Q; Zhao X; Liu Y; Sun B
Hum Pathol; 2010 Aug; 41(8):1186-95. PubMed ID: 20381828
[TBL] [Abstract][Full Text] [Related]
11. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome.
Iwaya K; Ogawa H; Izumi M; Kuroda M; Mukai K
Virchows Arch; 2002 Jun; 440(6):589-93. PubMed ID: 12070597
[TBL] [Abstract][Full Text] [Related]
12. CD24 expression has a prognostic impact in breast carcinoma.
Athanassiadou P; Grapsa D; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
Pathol Res Pract; 2009; 205(8):524-33. PubMed ID: 19243896
[TBL] [Abstract][Full Text] [Related]
13. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
14. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
Heinonen M; Bono P; Narko K; Chang SH; Lundin J; Joensuu H; Furneaux H; Hla T; Haglund C; Ristimäki A
Cancer Res; 2005 Mar; 65(6):2157-61. PubMed ID: 15781626
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
17. Cigarette smoking and metallothionein expression in invasive breast carcinomas.
Gallicchio L; Flaws JA; Sexton M; Ioffe OB
Toxicol Lett; 2004 Sep; 152(3):245-53. PubMed ID: 15331133
[TBL] [Abstract][Full Text] [Related]
18. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
[TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor II in female breast cancer as related to established prognostic factors and long-term prognosis.
Toropainen EM; Lipponen PK; Syrjanen KJ
Anticancer Res; 1995; 15(6B):2669-74. PubMed ID: 8669844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
